Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX).

Yves Rinaldi,Anne-Laure Pointet,Faiza Khemissa Akouz,Karine Le Malicot, Bidaut Wahiba,Samy Louafi,Alain Gratet,Laurent Miglianico, Hortense Laharie,Karine Bouhier Leporrier,Anne Thirot Bidault,Patrick Texereau,Romain Coriat,Eric Terrebonne,Marie-Claude Gouttebel,David Malka,Jean-Baptiste Bachet,Côme Lepage,Julien Taieb

European Journal of Cancer（2020）

引用 5|浏览49

暂无评分

摘要

•Sequential regimens every 2 months may overcome resistance to treatment in mPC.•Improved oncological outcomes were seen with the predefined sequential treatment.•Careful patient selection in future mPC clinical trials is of major importance.

查看译文

关键词

Sequential treatment,Pancreatic cancer,FOLFIRI.3,Nab-paclitaxel,Gemcitabine

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要